BsmI polymorphism of the vitamin D receptor gene in non-alcoholic fatty liver disease associated with type 2 diabetes mellitus
Abstract. Genetic variations associated with the vitamin D – vitamin D receptor (VDR) direction may play a role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, the impact of VDR gene polymorphisms on liver pathology has been poorly studied.A.V. Yagoda, E.O. Demurcheva, P.V. Koroy, T.R. Dudov
The aim: to investigate the association between BsmI polymorphism of the VDR gene and the manifestations of NAFLD in patients with type 2 diabetes mellitus (T2DM).
Material and methods. 167 patients with T2DM and 101 apparently healthy individual (control group) were included in the study. NAFLD was detected in 76.0% of patients with T2DM. Severe liver steatosis was observed in 30.7% of cases, F3–4 fibrosis was observed in 14.2% of NAFLD cases. Blood vitamin D levels were assessed using enzyme-linked immunosorbent assay, BsmI single-nucleotide polymorphism (rs1544410, A>G) of VDR gene was studied using PCR analysis.
Results. BsmI polymorphism of the VDR gene was not associated with the development of NAFLD in patients with T2DM. AA genotype and A allele of the BsmI polymorphism were associated with an increased risk of cytolytic syndrome and F3–4 liver fibrosis in the presence of NAFLD. The risk of obesity, abdominal obesity, and metabolic syndrome was reduced in NAFLD patients with GG genotype and allele G. BsmI polymorphism of the VDR gene was not associated with T2DM characteristics, presence of dyslipidemia, hypertension, or the severity of steatosis in case of NAFLD.
Conclusion. BsmI polymorphism of the VDR gene is associated with obesity, abdominal obesity, metabolic syndrome, the presence of cytolytic syndrome, and F3–4 liver fibrosis in patients with NAFLD that developed in the presence of T2DM.
Keywords
non-alcoholic fatty liver disease
type 2 diabetes mellitus
liver fibrosis
vitamin D receptor
BsmI polymorphism of the VDR gene
References
1. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835.
PMID: 36727674. PMCID: PMC10735173. https://doi.org/10.1097/HEP.0000000000000323
2. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology. 2023;77(4):1335–447.
PMID: 36626630. PMCID: PMC10026948. https://doi.org/10.1097/HEP.0000000000000004
3. Драпкина О.М., Евстифеева С.Е., Шальнова С.А., Куценко В.А., Баланова Ю.А., Имаева А.Э. с соавт. Распространенность неалкогольной жировой болезни печени и ее ассоциации с сердечно-сосудистыми факторами риска (данные российских эпидемиологических исследований). Кардиоваскулярная терапия и профилактика. 2025;24(2):6–16. (Drapkina OM, Evstifeeva SE, Shalnova SA, Kutsenko VA, Balanova YuA, Imaeva AE et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular risk factors (data from Russian epidemiological studies). Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2025;24(2):6–16 (In Russ.)).
EDN: CVQNXA. https://doi.org/10.15829/1728-8800-2025-4316
4. Aggeletopoulou I, Tsounis EP, Triantos C. Vitamin D and metabolic dysfunction-associated steatotic liver disease (MASLD): Novel mechanistic insights. Int J Mol Sci. 2024;25(9):4901.
PMID: 38732118. PMCID: PMC11084591. https://doi.org/10.3390/ijms25094901
5. Barchetta I, Cimini FA, Cavallo MG. Vitamin D and metabolic dysfunction-associated fatty liver disease (MAFLD): An update. Nutrients. 2020;12(11):3302.
PMID: 33126575. PMCID: PMC7693133. https://doi.org/10.3390/nu12113302
6. Lee S, Jin MH, Yoon JH. The contribution of vitamin D insufficiency to the onset of steatotic liver disease among individuals with metabolic dysfunction. Sci Rep. 2024;14(1):6714.
PMID: 38509247. PMCID: PMC10954610. https://doi.org/10.1038/s41598-024-57380-9
7. Yagoda AV, Koroy PV, Demurcheva EO, Hvatalin NE, Svetogurova AD, Sarithala VJ. Vitamin D as a marker of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Medical News of North Caucasus. 2023;18(2):131–135.
EDN: LUZTVN. https://doi.org/10.14300/mnnc.2023.18028
8. Zhao X, Sun J, Xin S, Xu X, Zhang X. Correlation between serum 25 (OH) D levels with insulin resistance and metabolic associated fatty liver disease – a retrospective study based on Chinese patients with newly diagnosed type 2 diabetes mellitus. Curr Diabetes Rev. 2025;21(7):56–66.
PMID: 38956910. https://doi.org/10.2174/0115733998297640240611065605
9. Huang N, Su X, Yu T, Wu X, Lu B, Sun W et al. Serum 25-hydroxy vitamin D level is associated with elastography-detected liver fibrosis in patients with type 2 diabetes mellitus in China. Front Endocrinol (Lausanne). 2024;15:1420088.
PMID: 39698035. PMCID: PMC11653015. https://doi.org/10.3389/fendo.2024.1420088
10. Yu H, Su X, Tao W, Sun W, Zhang X, Han Q et al. Prevalence and characteristics of liver steatosis and fibrosis in type 2 diabetes mellitus (T2DM) patients: A cross-sectional study in populations of eastern China. BMJ Open. 2024;14(12):e087550.
PMID: 39672583. PMCID: PMC11647396. https://doi.org/10.1136/bmjopen-2024-087550
11. Heo NJ, Park HE, Yoon JW, Kwak MS, Yang JI, Chung SJ et al. The association between vitamin D and nonalcoholic fatty liver disease assessed by controlled attenuation parameter. J Clin Med. 2021;10(12):2611.
PMID: 34199258. PMCID: PMC8231966. https://doi.org/10.3390/jcm10122611
12. Saberi B, Dadabhai AS, Nanavati J, Wang L, Shinohara RT, Mullin GE. Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A PRISMA compliant systematic review and meta-analysis of pooled data. World J Hepatol. 2018;10(1):142–54.
PMID: 29399288. PMCID: PMC5787678. https://doi.org/10.4254/wjh.v10.i1.142
13. Barchetta I, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. BMC Med. 2016;14:92.
PMID: 27353492. PMCID: PMC4926287. https://doi.org/10.1186/s12916-016-0638-y
14. Guo XF, Wang C, Yang T, Li S, Li KL, Li D. Vitamin D and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Food Funct. 2020;11(9):7389–99.
PMID: 32966467. https://doi.org/10.1039/d0fo01095b
15. Tao T, Kobelski MM, Saini V, Demay MB. Adipose-specific VDR deletion leads to hepatic steatosis in female mice fed a low-fat diet. Endocrinology. 2022;163(2):bqab249.
PMID: 34878523. PMCID: PMC10061053. https://doi.org/10.1210/endocr/bqab249
16. Tourkochristou E, Mouzaki A, Triantos C. Gene polymorphisms and biological effects of vitamin D receptor on nonalcoholic fatty liver disease development and progression. Int J Mol Sci. 2023;24(9):8288.
PMID: 37175993. PMCID: PMC10179740. https://doi.org/10.3390/ijms24098288
17. Tourkochristou E, Tsounis EP, Tzoupis H, Aggeletopoulou I, Tsintoni A, Lourida T et al. The influence of single nucleotide pol-ymorphisms on vitamin D receptor protein levels and function in chronic liver disease. Int J Mol Sci. 2023;24(14):11404.
PMID: 37511164. PMCID: PMC10380285. https://doi.org/10.3390/ijms241411404
18. Jaroenlapnopparat A, Suppakitjanusant P, Ponvilawan B, Charoenngam N. Vitamin D-related genetic variations and nonalcoholic fatty liver disease: A systematic review. Int J Mol Sci. 2022;23(16):9122.
PMID: 36012386. PMCID: PMC9409408. https://doi.org/10.3390/ijms23169122
19. Zhang R, Wang M, Wang M, Zhang L, Ding Y, Tang Z et al. Vitamin D level and vitamin D receptor genetic variation were involved in the risk of non-alcoholic fatty liver disease: A case-control study. Front Endocrinol (Lausanne). 2021;12:648844.
PMID: 34421816. PMCID: PMC8377425. https://doi.org/10.3389/fendo.2021.648844
20. Gibson PS, Quaglia A, Dhawan A, Wu H, Lanham-New S, Hart KH et al. Vitamin D status and associated genetic poly-morphisms in a cohort of UK children with non-alcoholic fatty liver disease. Pediatr Obes. 2018;13(7):433–41.
PMID: 29761652. PMCID: PMC6032876. https://doi.org/10.1111/ijpo.12293
21. Jamka M, Arslanow A, Bohner A, Krawczyk M, Weber SN, Grünhage F et al. Effects of gene variants controlling vitamin D metabolism and serum levels on hepatic steatosis. Digestion. 2018;97(4):298–308.
PMID: 29514138. https://doi.org/10.1159/000485180
22. Arai T, Atsukawa M, Tsubota A, Koeda M, Yoshida Y, Okubo T et al. Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. Dig Liver Dis. 2019;51(7):1036–42.
PMID: 30683615. https://doi.org/10.1016/j.dld.2018.12.022
23. Yaghooti H, Ghanavati F, Seyedian SS, Cheraghian B, Mohammadtaghvaei N. The efficacy of calcitriol treatment in non-alcoholic fatty liver patients with different genotypes of vitamin D receptor FokI polymorphism. BMC Pharmacol Toxicol. 2021;22(1):18.
PMID: 33827700. PMCID: PMC8028246. https://doi.org/10.1186/s40360-021-00485-y
24. Wang M, Wang M, Zhang R, Shen C, Zhang L, Ding Y et al. Influences of vitamin D levels and vitamin D-binding protein polymorphisms on nonalcoholic fatty liver disease risk in a Chinese population. Ann Nutr Metab. 2022;78(2):61–72.
PMID: 35100585. PMCID: PMC9116593. https://doi.org/10.1159/000522193
25. Arhin-Aidoo F, Fondjo LA, Obirikorang C, Owiredu EW, Senu E, Agomuo SKS, Laing EF. Association between vitamin D receptor gene variants and the risk of type 2 diabetes mellitus in a Ghanaian population. Sci Rep. 2025;15(1):26775.
PMID: 40702130. PMCID: PMC12287319. https://doi.org/10.1038/s41598-025-96731-y
26. Fatma H, Abdul SN. Association of vitamin D receptor gene BsmI polymorphism with type 2 diabetes mellitus in Pakistani population. Afr Health Sci. 2019;19(2):2164–71.
PMID: 31656501. PMCID: PMC6794500. https://doi.org/10.4314/ahs.v19i2.41
27. Gholami A, Montazeri-Najafabady N, Karimzadeh I, Dabbaghmanesh MH, Talei E. The effect of BsmI (rs1544410) single nucleotide polymorphism of vitamin D receptor (VDR) on insulin resistance in healthy children and adolescents: A cross-sectional study. BMC Pediatr. 2024;24(1):54.
PMID: 38233797. PMCID: PMC10792823. https://doi.org/10.1186/s12887-023-04503-2
28. Fteah AM, Mamdouh S, El-Shishtawy S, Sherif N, Aly DM. Role of vitamin D receptor genetic variants (ApaI and FokI) in association with nephropathy stages in a group of Egyptian patients with type 2 diabetes mellitus. Egypt J Immunol. 2025;32(2):57–69.
PMID: 40277331. https://doi.org/10.55133/eji.320206
29. Mitu MM, Toma TR, Nesa F, Rumpa FT, Khan F, Akter KA et al. Analysis of genetic association of vitamin D receptor (VDR) gene FokI polymorphism in Bangladeshi patients with type 2 diabetes mellitus. Gene. 2024;930:148863.
PMID: 39153706. https://doi.org/10.1016/j.gene.2024.148863
30. Sharifi A, Nouri M, Shakiba E, Ghorbani Z, Rahimi Z. The association of VDR FokI T>C (rs2228570) gene variants with T2DM, and its complications: Influence on BMI, oxidative stress, and dyslipidemia. J Clin Lab Anal. 2025;39(19):e70090.
PMID: 41020561. PMCID: PMC12514974. https://doi.org/10.1002/jcla.70090
31. Scalioni LP, Santos BRD, Spritzer PM, Villela-Nogueira CA, Laura Lewis-Ximenez L, Pollo-Flores P et al. Impact of vitamin D receptor and binding protein gene polymorphisms in clinical and laboratory data of HCV patients: Cross sectional study. Medicine (Baltimore). 2018;97(8):e9881.
PMID: 29465575. PMCID: PMC5842007. https://doi.org/10.1097/MD.0000000000009881
32. Triantos C, Aggeletopoulou I, Kalafateli M, Spantidea PI, Vourli G, Diamantopoulou G et al. Prognostic significance of vitamin D receptor (VDR) gene polymorphisms in liver cirrhosis. Sci Rep. 2018;8(1):14065.
PMID: 30218108. PMCID: PMC6138740. https://doi.org/10.1038/s41598-018-32482-3
33. Tsounis EP, Tourkochristou E, Sapsani A, Aggeletopoulou I, Lourida T, Ζisimopoulos Κ et al. The role of vitamin D receptor polymorphisms in the course of chronic hepatitis C infection. Ann Gastroenterol. 2022;35(2):203–12.
PMID: 35479594. PMCID: PMC8922255. https://doi.org/10.20524/aog.2022.0697
34. Nam SW, Choi J, Jeon HJ, Oh TK, Lee DH. The associations between vitamin D receptor BsmI and ApaI polymorphisms and obesity in Korean patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2021;14:557–64.
PMID: 33603421. PMCID: PMC7882455. https://doi.org/10.2147/DMSO.S293032
35 Jin T, Lu W, Gong X, Zhou J, Wu F. Association of vitamin D receptor polymorphisms with metabolic syndrome-related components: A cross-sectional study. J Clin Lab Anal. 2021;35(7):e23829.
PMID: 34008880. PMCID: PMC8275005. https://doi.org/10.1002/jcla.23829
36. Zhao Y, Liu Z, Feng S, Yang R, Ran Z, Zhu R et al. The association between vitamin D receptor gene polymorphism FokI and type 2 diabetic kidney disease and its molecular mechanism: A case control study. BMC Med Genomics. 2024;17(1):288.
PMID: 39696279. PMCID: PMC11658427. https://doi.org/10.1186/s12920-024-02061-9
37. Ozhan B, Bilgihan E, Cetin O, Agladıoglu K. The relation of vitamin D receptor gene polymorphisms with risk of obesity, metabolic syndrome, hepatostetosis in Turkish children. Pamukkale Med J. 2023;16(2):274–80.
https://doi.org/10.31362/patd.1249471
38. Ozsoy S, Yigit S, Nursal AF, Ozsoy Z, Dasiran MF, Daldal E, Tekcan A. Genetic association of the BsmI variant of vitamin D receptor gene with risk of morbid obesity. Rev Assoc Med Bras (1992). 2024;70(6):e20231020.
PMID: 39045947. PMCID: PMC11288276. https://doi.org/10.1590/1806-9282.20231020
39. Hasan HA, AbuOdeh RO, Muda WAMBW, Mohamed HJBJ, Samsudin AR. Association of vitamin D receptor gene polymorphisms with metabolic syndrome and its components among adult Arabs from the United Arab Emirates. Diabetes Metab Syndr. 2017;11 Suppl 2:S531–S537.
PMID: 28392355. https://doi.org/10.1016/j.dsx.2017.03.047
40. Корой П.В., Ягода А.В., Дудов ТР. Значение матриксных металлопротеиназ и их ингибиторов в прогнозировании фиброза F4 (цирроза) при хронических заболеваниях печени. Терапия. 2025;11(1):108–115. (Koroy PV, Yagoda AV, Dudov TR. The importance of matrix metallo-proteinases and their inhibitors in predicting f4 fibrosis (cirrhosis) in case of chronic hepatic disorders. Terapiya = Therapy. 2025;11(1):108–115 (In Russ.)).
EDN: NLRQKC. https://dx.doi.org/10.18565/therapy.2025.1.108-115
41. Ягода А.В., Корой П.В., Дудов Т.Р. Матриксные металлопротеиназы и морфологическая картина при хронических заболеваниях печени. Экспериментальная и клиническая гастроэнтерология. 2023;(10):153–159. (Yagoda AV, Koroy PV, Dudov TR. Matrix metalloproteinases and morphological features in chronic liver diseases. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2023;(10):153–159 (In Russ.)).
EDN: YACTWG. https://doi.org/10.31146/1682-8658-ecg-218-10-153-159
About the Authors
Alexander V. Yagoda, MD, Dr. Sci. (Medicine), professor, Honored Scientist of the Russian Federation, head of the Department of hospital therapy, Stavropol State Medical University, Stavropol, Russian Federation.E-mail: alexander.yagoda@gmail.com
ORCID: https://orcid.org/0000-0002-5727-1640. Scopus ID: 7007153293. eLibrary SPIN: 9651-9754
Elena O. Demurcheva, MD, endocrinologist at Regional endocrinology dispensary, Stavropol, Russian Federation.
E-mail: demurcheva.elena@yandex.ru
ORCID: https://orcid.org/0009-0007-7590-6201
Pavel V. Koroy, MD, Dr. Sci. (Medicine), professor, professor of the Department of hospital therapy, Stavropol State Medical University, Stavropol, Russian Federation.
E-mail: paule75@yandex.ru
ORCID: https://orcid.org/0000-0001-6392-8461. Scopus ID: 56288630200. eLibrary SPIN: 3313-7866
Temirlan R. Dudov, MD, PhD (Medicine), assistant at the Department of hospital therapy, Stavropol State Medical University, Stavropol, Russian Federation.
E-mail:timur222123@mail.ru
ORCID: https://orcid.org/0009-0006-7244-3507. eLibrary SPIN: 1608-7287
Similar Articles
